<DOC>
	<DOCNO>NCT01708707</DOCNO>
	<brief_summary>The purpose study determine whether buprenorphine beneficial , safe , cost effective treatment alternative morphine sulfate treatment Neonatal Abstinence Syndrome ( NAS ) .</brief_summary>
	<brief_title>Comparison Buprenorphine Morphine Treatment Neonatal Abstinence Syndrome ( NAS )</brief_title>
	<detailed_description>Neonatal abstinence syndrome condition affect newborn expose chronic opioid drug mother 's uterus ( womb ) prior birth . The current standard care treatment include morphine sulfate . Buprenorphine drug use adult treat narcotic dependence withdrawal , yet approve use newborn treatment alternative Neonatal Abstinence Syndrome . This investigation design measure sublingual ( tongue ) buprenorphine able reduce hospital length stay decrease number day drug treatment currently require treatment NAS . Another goal understand buprenorphine cost effective treatment NAS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Substance Withdrawal Syndrome</mesh_term>
	<mesh_term>Neonatal Abstinence Syndrome</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Infants correct gestational age ≥37 week Chronic opioid exposure utero Signs symptom NAS require treatment 2 consecutive Finnegan score ≥8 single score ≥12 Concomitant maternal benzodiazepine alcohol use 30 day prior enrollment Lifethreatening congenital malformation Intrauterine growth retardation Seizure activity congenital neurologic abnormality Concomitant neonatal use Cytochrome P450 inhibitor inducer prior treatment Inability mother 's consent due alter mental status comorbid psychiatric disorder Neonatal administration morphine prior enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>